EurekAlert! -
2 Mar 2020 07:00
(Mayo Clinic) The density of immune cells, called tumor infiltrating lymphocytes, when combined with analysis of tumor budding may serve as a method to more accurately predict survival in patients with stage III colon cancer. The findings, by a team of researchers led by Mayo Clinic gastroenterologist and oncologist, Frank Sinicrope, M.D., were published today in Annals of Oncology.
Share this Article
Comment on this Article
Please to comment